K-CAB Now Available in 35 Countries
HK inno.N has licensed out K-CAB, a novel drug for GERD that has Tegoprazan as its active ingredient, to Eurofarma, a major pharmaceutical firm in Brazil, the company announced on Jan. 26.
Eurofarma is the third-largest pharmaceutical firm in Latin America, with operations in 20 different countries in the region.
K-CAB has now entered a total of 35 countries around the world. The most recent launch was in the Philippines, following the launch in China.
HK inno.N president Kwak Dal-won commented, “K-CAB has been seeing great progress in recent years in international markets, in terms of export contracts, follow-up clinical studies, approvals and market launches. HK inno.N’s goal is to make the product available in 100 countries by the year 2028. We are doubling down on our global business to meet that goal.”
“The partnership will bring benefits to prescribers and patients as it is a high-tech and effective medicine,” says Martha Penna, Eurofarma’s Innovation VP. “The announcement reinforces the movement undertaken by Eurofarma for new partnerships regarding innovation and globalization.”
K-CAB, a novel drug to treat GERD, falls within the category of P-CAB drugs and has already been a big hit in its native Korean market. A total of 125.2 billion won worth of prescriptions for K-CAB have been written for outpatients in Korea last year alone in Korea. The quick onset time of just 30 minutes and the proven efficacy and safety even when taken for a longer period of six months make the drug particularly appealing.
Meanwhile, HK inno.N has obtained approval for K-CAB in Mongolia, Indonesia and Singapore, and approvals are ongoing or in preparations in 27 countries including Mexico. Development to gear up for local manufacturing is underway in the three countries of the United States, Canada and Brazil.